Recent Investment Analysts’ Ratings Changes for Kymera Therapeutics (KYMR)

A number of research firms have changed their ratings and price targets for Kymera Therapeutics (NASDAQ: KYMR):

• 10/15/2026 – Kymera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/8/2026 – Kymera Therapeutics is now covered by Raymond James Financial. They set an “outperform” rating and a $140.00 price target on the stock.
• 10/8/2026 – Kymera Therapeutics is now covered by Raymond James Financial. They set an “outperform” rating and a $140.00 price target on the stock.
• 10/5/2026 – Kymera Therapeutics had its price target raised by Citigroup from $135.00 to $150.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Kymera Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $140.00 price target on the stock.
• 9/22/2026 – Kymera Therapeutics had its price target raised by Stifel Nicolaus from $132.00 to $152.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Kymera Therapeutics had its price target raised by Bank of America from $123.00 to $144.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Kymera Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $180.00 price target on the stock.
• 8/31/2026 – Kymera Therapeutics had its price target raised by Guggenheim from $135.00 to $170.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Kymera Therapeutics had its price target raised by Wells Fargo & Company from $116.00 to $151.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This represents a 4.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Adams sold 6,371 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is owned by insiders.

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.